Profile data is unavailable for this security.
About the company
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. Halo-Lido is a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids. Mino-Wrap is a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries. NoveCite is a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.
- Revenue in USD (TTM)0.00
- Net income in USD-39.33m
- Incorporated2010
- Employees22.00
- LocationCitius Pharmaceuticals Inc11 Commerce Dr Fl 1CRANFORD 07016-3501United StatesUSA
- Phone+1 (908) 967-6677
- Websitehttps://www.citiuspharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adicet Bio Inc | 0.00 | -142.66m | 119.15m | 143.00 | -- | 0.3687 | -- | -- | -3.32 | -3.32 | 0.00 | 3.93 | 0.00 | -- | -- | 0.00 | -53.03 | -37.03 | -57.18 | -40.28 | -- | -- | -- | -748.46 | -- | -- | 0.00 | -- | -100.00 | -- | -104.41 | -- | 65.27 | -- |
| Vistagen Therapeutics Inc | 1.04m | -32.07m | 121.61m | 37.00 | -- | 0.9864 | -- | 116.68 | -3.56 | -3.56 | 0.0775 | 4.56 | 0.013 | -- | -- | 31,584.85 | -39.89 | -77.80 | -42.10 | -85.00 | -- | -- | -3,076.62 | -8,640.25 | -- | -- | 0.00006 | -- | -120.50 | -- | -21.64 | -- | 165.73 | -- |
| Leap Therapeutics Inc | 0.00 | -81.41m | 122.05m | 54.00 | -- | 1.36 | -- | -- | -5.11 | -5.11 | 0.00 | 2.35 | 0.00 | -- | -- | 0.00 | -113.72 | -80.06 | -136.52 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
| Vor Biopharma Inc | 0.00 | -117.86m | 122.79m | 168.00 | -- | 0.8108 | -- | -- | -1.75 | -1.75 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -47.38 | -45.79 | -50.28 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Immunic Inc | 0.00 | -93.61m | 123.41m | 77.00 | -- | 2.14 | -- | -- | -2.11 | -2.11 | 0.00 | 0.6404 | 0.00 | -- | -- | 0.00 | -102.84 | -72.09 | -129.79 | -80.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 22.25 | -- | -10.97 | -- |
| Abeona Therapeutics Inc | 3.50m | -54.19m | 125.83m | 84.00 | -- | 8.23 | -- | 35.95 | -2.59 | -2.59 | 0.1639 | 0.559 | 0.0546 | -- | 2.66 | 41,666.67 | -84.53 | -53.22 | -101.27 | -65.81 | -- | -- | -1,548.23 | -1,894.25 | -- | -- | 0.00 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Vaxart Inc | 7.38m | -82.47m | 126.73m | 109.00 | -- | 1.93 | -- | 17.17 | -0.5844 | -0.5844 | 0.0519 | 0.3767 | 0.0601 | -- | 4.87 | 67,697.25 | -67.13 | -49.60 | -77.06 | -54.86 | -- | -- | -1,117.56 | -1,398.00 | -- | -- | 0.10 | -- | 6,796.26 | 12.15 | 23.47 | -- | 21.49 | -- |
| Coya Therapeutics Inc | 6.00m | -7.99m | 126.75m | 8.00 | -- | 3.51 | -- | 21.12 | -0.8219 | -0.8219 | 0.5906 | 2.47 | 0.2417 | -- | -- | 750,276.30 | -32.17 | -- | -39.17 | -- | -- | -- | -133.08 | -- | -- | -- | 0.00 | -- | -- | -- | 34.77 | -- | -- | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.33m | 127.18m | 22.00 | -- | 1.32 | -- | -- | -0.255 | -0.255 | 0.00 | 0.533 | 0.00 | -- | -- | 0.00 | -36.52 | -30.26 | -38.61 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| FitLife Brands Inc | 52.70m | 5.30m | 128.52m | 37.00 | 25.85 | 4.75 | 23.84 | 2.44 | 1.08 | 1.08 | 10.74 | 5.88 | 1.30 | 3.44 | 38.31 | 1,424,297.00 | 13.07 | 26.40 | 15.94 | 33.92 | 40.67 | 42.09 | 10.05 | 17.65 | 0.5419 | 16.81 | 0.4253 | -- | 82.97 | 25.28 | 19.58 | 67.31 | -- | -- |
| Biostem Technologies Inc | 16.69m | -7.86m | 129.72m | 67.00 | -- | -- | -- | 7.77 | -0.5699 | -0.5699 | 1.21 | -0.0607 | -- | -- | -- | -- | -- | -- | -- | -- | 92.44 | -- | -47.12 | -- | 0.7825 | -10.22 | 1.26 | -- | -- | -- | -- | -- | -- | -- |
| Karyopharm Therapeutics Inc | 146.03m | -143.10m | 131.61m | 325.00 | -- | -- | -- | 0.9012 | -1.25 | -1.25 | 1.28 | -1.19 | 0.4879 | 1.36 | 3.94 | 449,332.30 | -47.81 | -53.02 | -61.78 | -65.85 | 96.62 | 97.18 | -97.99 | -125.15 | 3.32 | -10.06 | 1.81 | -- | -7.03 | 36.93 | 13.43 | -- | -- | -- |
| Elite Pharmaceuticals Inc | 47.32m | 15.55m | 132.12m | 53.00 | 8.51 | 2.85 | 7.81 | 2.79 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
| Rezolute Inc | 0.00 | -56.83m | 132.82m | 51.00 | -- | 1.43 | -- | -- | -1.11 | -1.11 | 0.00 | 2.31 | 0.00 | -- | -- | 0.00 | -45.04 | -58.48 | -47.75 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
Data as of May 03 2024. Currency figures normalised to Citius Pharmaceuticals Inc's reporting currency: US Dollar USD
14.44%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 7.84m | 4.93% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 6.78m | 4.26% |
| Geode Capital Management LLCas of 31 Dec 2023 | 2.78m | 1.75% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.21m | 1.39% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 1.05m | 0.66% |
| American Portfolios Advisors, Inc.as of 31 Dec 2023 | 895.55k | 0.56% |
| Teachers Advisors LLCas of 31 Dec 2023 | 484.65k | 0.31% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2023 | 356.99k | 0.22% |
| BlackRock Investment Management LLCas of 31 Dec 2023 | 333.80k | 0.21% |
| The Bank of New York Mellon Corp. (Investment Management)as of 31 Mar 2024 | 239.16k | 0.15% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
